|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Interestingly, all 3 members affected by PTC harbored the p.V600E somatic mutation in BRAF.
|
29895015 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Immunohistochemical detection of the mutated BRAF V600E protein in PTC may facilitate mutational analysis in the clinical setting.
|
29254799 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The mRNA and protein levels of MMP-9 had no association with BRAF V600E mutation in Iranian PTC patients.
|
30509240 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The positive correlation observed between expression of BRAF V600E and PD-L1/PD-1 suggests that immunotherapies targeting PD-L1/PD-1 might be effective for PTC patients with the BRAF V600E mutation, which are refractory to radioiodine therapy.
|
29651624 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (<sup>131</sup>I) therapy: Should we modify our therapeutic strategy?
|
29567362 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Of 16 cases (12 benign, 3 FTC, 1 PTC) with surgical correlation, 15 had solitary TSHR mutations and 1 PTC had comutation with BRAF V600E.
|
29516685 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Conclusion The long-observed age-associated mortality risk in PTC is dependent on BRAF status; age is a strong, continuous, and independent mortality risk factor in patients with BRAF V600E mutation but not in patients with wild-type BRAF.
|
29240540 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Presence of BRAF V600E mutation was identified in 20 samples of PTC of 40 (50%).
|
30449496 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this study, we used the KTC1 cell line as a model for human advanced papillary thyroid cancer (PTC) because the cells harbor the heterozygous BRAF (V600E) mutation together with the C250T TERT promoter mutation.
|
30265861 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Expression of BRAF V600E, RET/PTC, and c</span>oncomitant expression of BRAF V600E and RET/PTC were significantly associated with patient age and lymph node metastasis (P<0.05).
|
30254191 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
|
29165667 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
|
30219154 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Purpose:</b> Sixty percent of papillary thyroid cancers (PTC) have an oncogenic (V600E) BRAF mutation.
|
30065097 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Conclusion Male sex is a robust independent risk factor for PTC-specific mortality in BRAF V600E patients but not in wild-type BRAF patients.
|
30070937 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In summary, BRAF V600E-activated MAP kinase pathway causes hypomethylation and overexpression of WIPF1; WIPF1 then functions like an oncoprotein to robustly promote aggressive cellular and tumor behaviors of PTC.
|
27863429 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
CD70 expression was associated with the presence of a precursor papillary thyroid carcinoma and the presence of BRAF V600E mutations in the anaplastic thyroid cancer lesion.
|
28383817 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Our data are consistent with those of other studies reporting a positive relation between BRAF V600E mutation and poor prognostic factors in PTC; however, the BRAF status did not significantly correlate with a response to therapy.
|
28718951 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Papillary thyroid carcinoma samples with BRAF V600E mutation were shown to have higher glucose transporter 1, hexokinase II, carbonic anhydrase IX, and tumoral monocarbonylate transporter 4 expression levels.
|
28347233 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer.
|
27919446 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Few authors demonstrated that some architectural and specific cellular findings (i.e. polygonal eosinophilic cells defined as "plump cells" and sickle-shaped nuclei) are able to predict BRAF V600E mutation in both cytological and histological samples of papillary thyroid carcinoma (PTC) as well as in other carcinomas.
|
27738305 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
99 PTC and 11 nodular hyperplasia FFPE thyroid tissues are evaluated for the BRAF V600E mutation by the Idylla tests and compared with peptide nucleic acid-clamping PCR, real-time PCR and pyrosequencing.
|
27543599 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
By immunohistochemistry, TENM1 expression in papillary thyroid cancer was associated with the classical subtype (p = 0.018), extrathyroidal invasion (p = 0.001), BRAF V600E mutation (p < 0.001), and an advanced stage (p = 0.019).
|
28004221 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis.
|
28687736 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Of 221 PTC nodules, 150 (67.9%) on FNAC and 185 (83.7%) on FFPE samples were BRAF V600E mutation positive.
|
29132392 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We evaluated the molecular diagnostic (BRAF p.V600E mutation) results of 410 patients treated for PTC.
|
28636673 |
2017 |